20 June 2013
Keywords: Gilead Sciences, Ranexa, Angina, Diabetes patients, Ph IV
Article | 11 March 2013
US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes Evaluation of Ranolazine ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 March 2013
19 June 2013
© 2013 thepharmaletter.com